Skip to main content

Advertisement

Figure 3 | BMC Cancer

Figure 3

From: Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers

Figure 3

The prognostic significance of RRM2 for the public breast cancer microarray data sets and the ZJU set. Kaplan-Meier analysis for RRM2 mRNA levels and PFS of breast cancer patients in the Pawitan set (A) and Ivshina set (B). Breast cancer patients were stratified into four subgroups based on their RRM2 expression levels. Q1 was 0 to the 25th percentile; Q2 was the 25th percentile to the median; Q3 was the median to the 75th percentile; and Q4 was the 75th percentile to the maximum. The subgroups of Q1, Q2, Q3 and Q4 represent mRNA of RRM2 from low to high. The method used to stratify is described in Materials & Methods. The Cox analyses for RRM2, the 70-gene signature, wound-response gene signature, 21-gene recurrence score and TNM stage are shown for the NKI set (C). The protein expression levels of RRM2 in the ZJU set were determined by IHC and the standard scores are shown in (D). Multivariate Cox analysis for RRM2 levels and OS are shown in (E). * P < 0.05; **P < 0.01.

Back to article page